Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo® working party
- J. Alfred WitjesAffiliated withDepartment of Urology, Radboud University Nijmegen Medical Centre Email author
- , Kees HendricksenAffiliated withDepartment of Urology, Radboud University Nijmegen Medical Centre
- , O. GofritAffiliated withDepartment of Urology, Hadassah University Hospital
- , O. RisiAffiliated withDepartment of Urology, Ospedale Consorziale di Treviglio e Caravaggio
- , O. NativAffiliated withDepartment of Urology, Bnay-Zion Medical Center
To study the results of chemotherapy combined with intravesical hyperthermia in patients with mainly BCG-failing carcinoma in situ (CIS).
Patients with histologically confirmed CIS were included retrospectively. Outpatient thermochemotherapy treatment was done with mitomycin-C (MMC) and the Synergo® system SB-TS 101 (temperature range between 41 and 44°C), weekly for 6–8 weeks, followed by 4–6 sessions every 6–8 weeks.
Fifty-one patients were treated between 1997 and 2005 from 15 European centers. Thirty-four were pre-treated with BCG. Mean age was 69.9 years. Twenty-four patients had concomitant papillary tumors. The mean number of hyperthermia/MMC treatments per patient was 10.0. Of the 49 evaluable patients 45 had a biopsy and cytology proven complete response. In two patients CIS disappeared, but they had persistent papillary tumors. Follow-up of 45 complete responders showed 22 recurrences after a mean of 27 months (median 22): T2 (4), T1 (4), T1/CIS (1), CIS (5), Ta/CIS (2), Ta (5) and Tx (1). Side effects (bladder complaints) were generally mild and transient.
In patients with primary or BCG-failing CIS, treatment with intravesical hyperthermia and MMC appears a safe and effective treatment. The initial complete response rate is 92%, which remains approximately 50% after 2 years.
KeywordsBladder cancer CIS Hyperthermia Mitomycin-C Thermochemotherapy
- Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo® working party
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
World Journal of Urology
Volume 27, Issue 3 , pp 319-324
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Bladder cancer
- Industry Sectors
- Author Affiliations
- 1. Department of Urology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands
- 2. Department of Urology, Hadassah University Hospital, Jerusalem, Israel
- 3. Department of Urology, Ospedale Consorziale di Treviglio e Caravaggio, Treviglio, Italy
- 4. Department of Urology, Bnay-Zion Medical Center, Haifa, Israel